華安醫學股份有限公司
華安醫學股份有限公司（Ace Biotek）為一家新藥開發與科學儀器供應商。公司核心技術為「ENERGI 藥物研發平台」，透過增加細胞內 ATP 能量，促進受損細胞修復。核心新藥管線包含：治療糖尿病足潰瘍（F703）、防止落髮（F701）及巴金森氏症控制。除了醫藥開發，公司亦銷售高階生命科學實驗室用設備與化學試劑，提供生物技術諮詢與分析服務。公司成立於 2012 年，總部位於台灣台北市。
今日下跌 2.10%，股價跌破短期均線。該股 RSI(6) 為 33.3，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=46.2）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-11 | +10 | 0 | 0 | +10 |
| 08-10 | -40 | 0 | 0 | -40 |
| 08-07 | +19 | 0 | 0 | +19 |
| 08-06 | +5 | 0 | -1 | +4 |
| 08-05 | +2 | 0 | 0 | +2 |
| 08-04 | +32 | 0 | 0 | +32 |
| 08-03 | +5 | 0 | -2 | +3 |
| 07-31 | -18 | 0 | +1 | -17 |
| 07-30 | +24 | 0 | -1 | +23 |
| 07-29 | +211 | 0 | +1 | +212 |
| 07-28 | +100 | 0 | 0 | +100 |
| 07-27 | +18 | 0 | +1 | +19 |
| 07-24 | -50 | 0 | -1 | -51 |
| 07-23 | -4 | 0 | 0 | -4 |
| 07-22 | +22 | 0 | -1 | +21 |
| 07-21 | +67 | 0 | 0 | +67 |
| 07-20 | +80 | 0 | +1 | +80 |
| 07-17 | 0 | 0 | 0 | 0 |
| 07-16 | +63 | 0 | +1 | +64 |
| 07-15 | +35 | 0 | -3 | +32 |
| 07-14 | -1 | 0 | +4 | +3 |
| 07-13 | -18 | 0 | 0 | -18 |
| 07-09 | +1 | 0 | 0 | +1 |
| 07-08 | -18 | 0 | 0 | -18 |
| 07-06 | -13 | 0 | 0 | -13 |
| 07-03 | +91 | 0 | 0 | +91 |
| 07-02 | -11 | 0 | 0 | -11 |
| 07-01 | +23 | 0 | 0 | +23 |
| 06-30 | +38 | 0 | 0 | +38 |
| 06-29 | +28 | 0 | 0 | +28 |
| 06-26 | -24 | 0 | 0 | -24 |
| 06-25 | +58 | 0 | 0 | +58 |
| 06-24 | +57 | 0 | 0 | +57 |
| 06-22 | +45 | 0 | 0 | +45 |
| 06-18 | +4 | 0 | -1 | +3 |
| 06-17 | -37 | 0 | +2 | -35 |
| 06-16 | +81 | 0 | -1 | +80 |
| 06-15 | +47 | 0 | +2 | +49 |
| 06-12 | +30 | 0 | 0 | +30 |
| 06-10 | +13 | 0 | -1 | +12 |
| 06-09 | +9 | 0 | +1 | +10 |
| 06-08 | +23 | 0 | -2 | +21 |
| 06-04 | +6 | 0 | 0 | +6 |
| 06-03 | +82 | 0 | 0 | +82 |
| 06-02 | 0 | 0 | -3 | -3 |
| 06-01 | +40 | 0 | +1 | +41 |
| 05-29 | +15 | 0 | 0 | +15 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/06 | 50 萬 | -7.2% | -45.7% |
| 2026/05 | 54 萬 | -33.1% | -24.1% |
| 2026/04 | 81 萬 | +10.8% | +89.9% |
| 2026/03 | 73 萬 | +170.4% | +50.2% |
| 2026/02 | 27 萬 | -30.9% | -8.5% |
| 2026/01 | 39 萬 | -65.1% | -9.5% |
| 2025/12 | 112 萬 | +102.0% | +86.8% |
| 2025/11 | 56 萬 | -51.3% | -50.2% |
| 2025/10 | 114 萬 | +47.5% | +29.1% |
| 2025/09 | 77 萬 | +143.5% | +69.7% |
| 2025/08 | 32 萬 | -35.7% | -69.8% |
| 2025/07 | 49 萬 | - | -19.2% |